Galderma is set to showcase its latest advancements in dermatology at the 33rd European Academy of Dermatology and Venereology (EADV) congress in Amsterdam from September 25-28, 2024. The company will present 30 abstracts, underlining its leading position in the field and commitment to addressing key dermatological issues.
Nemolizumab, Galderma’s monoclonal antibody, will be at the forefront of their presentations. The drug, which is being explored for its impact on prurigo nodularis and atopic dermatitis, will feature in nine abstracts. Three late-breaking presentations will highlight its long-term efficacy and durability. Specifically, on September 25, 2024, findings on nemolizumab’s effectiveness in prurigo nodularis will be presented at 2:15 pm CET, followed by discussions on its efficacy in atopic dermatitis at 3:00 pm and 4:30 pm CET. The data aims to address the speed of onset, immunogenicity, and dosing of nemolizumab.
In addition to these presentations, Galderma will host a symposium and industry hub sessions focusing on itch management in prurigo nodularis and atopic dermatitis. The symposium, titled “Shifting the Paradigm in the Management of Atopic Dermatitis and Prurigo Nodularis: Expert Insights into the Unmet Need for Itch Control,” will take place on September 27, 2024, from 1:00 pm to 2:00 pm CET, chaired by Prof. Diamant Thaçi. The session will feature contributions from Prof. Sonja Ständer, Dr. Sarina Elmariah, and Dr. Andrew Pink. Additionally, an industry hub session on September 26, 2024, will discuss “Elevating Itch Monitoring in Atopic Dermatitis and Prurigo Nodularis” from 4:15 pm to 5:00 pm CET, hosted by experts including Prof. Jonathan Silverberg and Prof. Shawn Kwatra.
Beyond itch management, Galderma will present its latest research on sensitive skin, a condition that has been gaining attention since the establishment of the Global Sensitive Skincare Faculty (GSSF) in 2022. The session, “Decoding Sensitive Skin: Revolutionary Findings from the Broadest Worldwide Profiling Survey,” will provide insights from a global survey involving over 16,000 subjects. This event will be held on September 26, 2024, from 2:15 pm to 3:00 pm CET.
Further industry hub sessions will cover new tools for skin quality assessment and holistic acne management. The “New Skin Quality Assessment Scale – Looking Beyond the Disease” session will explore a new tool for evaluating skin quality, while the “OneAcne: A Holistic Management Approach” session will address comprehensive acne treatment strategies. These sessions are scheduled for September 26 and 27, respectively.
Galderma’s participation in EADV 2024 reflects its dedication to advancing dermatological care and addressing the real needs of patients through innovative research and solutions. For more details on Galderma’s presentations and activities at EADV, visit their website. For more information: www.galderma.com
